Results: MSYS

Search articles by EPIC code
EPIC MSYS
views

Microsaic Systems – trading “remains in line” & partnership phase 2 “completed successfully”, so why the share price fall?

An intra-day (11:20am) “Bioprocessing partnership update & trading update” from mass spectrometry instruments developer Microsaic Systems (MSYS). This firstly “confirms that trading in 2018 remains in line with the board's expectations” and then that phase two of the partnership “with a global partner in bioprocessing… has now been completed successfully, with a clear addressable market identified and positive feedback received from potential customers”. So why a 25% share price fall, towards 1p?...

EPIC MSYS
views

Microsaic Systems – from in December sales to be “substantially ahead” of 2016’s, to now “significantly lower than for 2016”

“Trading Statement” announcement from Microsaic Systems (MSYS) includes Chairman Eric Yeatman commenting “we are very encouraged with the progress since our 21 March 2017 update, when we introduced our biopharma strategy, specifically around bioprocessing. We are engaging with several of the leading players in the global market for bioprocessing equipment”. However, the statement also includes that “the company now expects its H1 and full year 2017 revenue to be significantly lower than for 2016”. Hmmm…

Page 2 of 3 (25 articles)
Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Complete Coverage

Recent Comments

|